Accelerated Approval Should Be “Conditional,” Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s accelerated approval process should be renamed “conditional approval,” according to members of FDA oncology advisory committee.
You may also be interested in...
“Conditional” Approval System Could Require Comparative Confirmatory Trials
NIH staffer suggests sponsors could be required to submit comparative effectiveness data after receiving conditional approval.
“Conditional” Approval System Could Require Comparative Confirmatory Trials
NIH staffer suggests sponsors could be required to submit comparative effectiveness data after receiving conditional approval.
Submitted Data Confirm Doxil's Clinical Benefit, J&J Maintains
FDA's Oncologic Drugs Advisory Committee will review on Nov. 8 unfulfilled accelerated approval trial commitments for products approved before 2002.